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In June 2017 a group of experts in anthropology, biology, kinesiology, neuroscience, 
physiology, and psychology convened in Canterbury, UK, to address questions relating to the 
placebo effect in sport and exercise. The event was supported exclusively by Quality Related 
(QR) funding from the Higher Education Funding Council for England (HEFCE). The funder did 
not influence the content or conclusions of the group. No competing interests were declared 
by any delegate. Jacob Lindheimer is with the US Department of Veterans Affairs. The 
contents of this paper do not represent the views of the Department of Veterans Affairs or 
of the United States Government. 
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USA); John Raglin (Kinesiology, Indiana University, USA); Bart Roelands (Neuroscience, Free 
University of Brussels, Belgium); Lieke Schiphof-Godart (The Hague University of Applied 
Sciences, The Netherlands); Attila Szabo (Psychology, ELTE Eötvös Loránd University, 
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During the meeting and in follow-up correspondence, all delegates agreed the need to 
communicate the outcomes of the meeting via a brief consensus statement. The two specific 
aims of this statement are to encourage researchers in sport and exercise science to:  
 
1. Where possible, adopt research methods that more effectively elucidate the role of 
the brain in mediating the effects of treatments and interventions. 
2. Where possible, adopt methods that factor for and/or quantify placebo effects that 
could explain a percentage of inter-individual variability in response to treatments 
and interventions.  
 
The contents of this statement were derived through two days of round-table discussion and 
by correspondence over the subsequent months. Although this document is not a 
comprehensive review of the literatures in question, we contend that the consensus 
statement is of value to scientists and practitioners given the broad expertise of the 
membership of the group. We are cognizant that given the state of the literature related to 
placebo effects in the sport and exercise literature, some may regard this statement to be 
premature. However, we believe that findings elsewhere render the piece both timely and 
important. Specifically, the absence of clear trends or theoretical frameworks in placebo 
effect research in sport and exercise has led to variations in definitions and concepts, which 
have constrained advances in knowledge. Our goal is to present recommendations built on 
what is known about placebo effects in a broad range of scientific disciplines, including 
anthropology, biology, medicine, neuroscience and psychology. By doing so we feel this will 
provide both a broader consensus of basic concepts and increase awareness of 
methodological challenges to facilitate advances in knowledge. This awareness and the 
resulting recommendations will have impacts on future sport and exercise studies, as they 




The placebo effect. The placebo effect is a desirable outcome resulting from a person’s 
expected and/or learned response to a treatment or situation. A nocebo effect is an 
undesirable outcome resulting from similarly learned or expected cues. Given that placebo 
effects are common in response to drugs, researchers in a broad range of disciplines, most 
notably medicine, have attempted to control for them for almost 80 years, with the first 
placebo controlled clinical trial reported in 1944 (Chalmers & Clarke, 2004). However, whilst 
the placebo effect has been controlled for almost ubiquitously in medicine since that study, 
research into the placebo effect itself was slow to develop.  
 
In a seminal review (Beecher, 1955), the significant influence of the placebo effect in a range 
of medical conditions was reported. Since then, and specifically since the mid-1990s, there 
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has been mounting evidence for the clinically meaningful contribution of placebo effects 
(Kirsch & Sapirstein, 1998), and for unambiguous and consistent neurophysiological 
pathways underlying these effects (Wager & Atlas, 2015).  This evidence has led many 
researchers to position the placebo condition in research as an active treatment, as opposed 
to either a passive control or a collective term for a range of non-specific effects such as 
regression to the mean (Finniss, Kaptchuk, Miller, & Benedetti, 2010). 
 
Placebo effects in sport and exercise. Reviews of the sport and exercise literature have 
reported beneficial effects associated with the administration of placebo treatments (Beedie 
& Foad, 2009; Bérdi, Köteles, Szabó, & Bárdos, 2011). Most published studies in sport 
focused on the effects of placebo nutritional supplements, including caffeine, creatine-
monohydrate, carbohydrate and even anabolic steroids. Whilst some studies reported the 
effects of the placebo against no treatment (Ariel & Saville, 1972; Beedie, Coleman, & Foad, 
2007), others directly compared the effects of the placebo with the substance which the 
placebo was described to be (Clark, Hopkins, Hawley, & Burke, 2000; McClung & Collins, 
2007). The majority of these studies reported positive effects of placebos on objective 
measures of performance outcome and subjective markers of physiological stress such as 
rating of perceived exertion (Duncan, 2010). Fewer studies have included objective markers 
of physiological stress such as blood lactate, oxygen uptake and heart rate (Foad, Beedie, & 
Coleman, 2008). Reviews of this literature (Beedie & Foad, 2009; Bérdi et al., 2011) indicate 
the findings of sport placebo research are generally consistent with those reported in other 
scientific disciplines such as medicine, psychiatry and neuroscience (for review see Pollo, 
Carlino, & Benedetti, 2011). These can be summarized as follows:  
 
1. Placebo effects in relation to baseline/no-treatment conditions are frequently 
observed in studies in which the placebo condition is treated as an experimental 
manipulation (Beedie & Foad, 2009; Bérdi et al., 2011). In short, when researchers 
and practitioners treat the placebo as a manipulation, they realise that standard 
control conditions are often not really controls. 
2. Effects are often of a magnitude that is meaningful to the athlete. That is, they are 
associated with a likely beneficial effect on performance or performance-related 
variables (Batterham & Hopkins, 2006; Beedie, Stuart, Coleman, & Foad, 2006). 
3. In many cases placebo effects constitute a significant percentage of the overall effect 
of the treatment the placebo purports to be, for example caffeine (Foad et al., 2008).  
4. Placebo effects constitute approximately 50% of the effects of exercise on both 
subjective (i.e., anxiety, depression, energy, fatigue) and/or objective (i.e., cognitive 
tasks) psychological outcomes (Lindheimer, O’Connor, & Dishman, 2015). 
 
Causes of placebo effects. Researchers in neuroscience, medicine and psychology have 
examined causes of placebo effects, and much of this work has focused on environmental 
cues of conditioning and/or expectation. Conditioning can be either conscious or 
unconscious learning resulting from the repeated pairing of a stimulus treatment and a 
response. Research on human performance reported in the neuroscience literature 
demonstrates effects of conditioned placebo responses of morphine (Benedetti, Pollo, & 
Colloca, 2007) and caffeine (Pollo, Carlino, & Benedetti, 2008) on muscle performance. 
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Expectation is conceived as a conscious cognitive process often resulting from verbal 
instruction. Work in sport and exercise science to date has generally adopted experimental 
designs based on expectation. Saunders et al. (2017) reported that the performance of 
subjects who, when asked post-test, identified correctly that they had ingested 
caffeine, improved to a greater degree than did that of subjects who had ingested caffeine 
but did not believe this to be the case. Hence, knowingly ingesting caffeine increases 
performance more than ingesting caffeine unknowingly. Furthermore, the same authors 
reported that the performance of subjects who believed they had ingested caffeine but who 
had actually ingested placebo improved compared to those who correctly identified that 
they had ingested placebo, the latter associated with performance decrements in some 
subjects. 
 
Neurobiological mechanisms of placebo effects. In arguably a landmark study (Levine, 
Gordon, & Fields, 1978) it was demonstrated that the placebo effect on pain could be 
reversed by administration of the opiate antagonist naloxone. This finding suggested not 
only that the placebo effect in this context had a clear neurobiological mechanism, but that 
the mechanism of placebo analgesia was what would be expected with a real analgesic 
treatment. Since this publication, an extensive body of research has shown not only that 
expectation and conditioning independently cause placebo effects, but that each operate via 
discrete neurophysiological pathways. In fact, this research has shown that there is not just 
one mechanism of the placebo effect, but several, each operating across different 
neurobiological pathways. For example, in a study of pain (Amanzio & Benedetti, 1999), the 
placebo effects were either experimentally conditioned, or resulted from experimentally 
induced expectations (conditioning was achieved by means of either the opioid agonist 
morphine hydrochloride, or the nonopioid ketorolac tromethamine). Expectation resulted in 
placebo responses that were completely blocked by the opioid antagonist naloxone, 
suggesting that the placebo effect in question was a function of opioid pathways. 
Expectation cues together with morphine conditioning also produced placebo responses 
that were completely blocked by naloxone, as did morphine conditioning alone. By contrast, 
ketorolac conditioning together with expectation cues elicited a placebo effect that was only 
partially blocked by naloxone, and ketorolac conditioning alone produced placebo responses 
that were naloxone-insensitive. Therefore, Amanzio and Benedetti elicited different types of 
placebo responses using different methods of induction, conditioning and expectation. 
These data, and findings of many other studies (for review see Benedetti & Dogue, 2015) 
indicate that placebo effects can be intact neurophysiological events, the mechanisms of 
which vary in relation to contextual cues, ultimately affecting activity in endogenous self-
regulatory systems. These are proposals that could, and perhaps should, be tested in sport 
and exercise, especially given that many of the variables examined in placebo effect research 
in neuroscience and elsewhere, such as pain, fatigue, and oxygen availability, have 
implications for both.   
 
The nocebo effect. Evidence suggests that the nocebo effect, an undesirable effect resulting 
from anticipated or conditioned negative outcomes, is also underpinned by neurobiological 
pathways (Tracey, 2010). For example, negative verbal suggestions induce anticipatory 
anxiety, which is associated with the activation of cholecystokinin (CCK) which in turn, 
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facilitates pain transmission. Analogous to work in endogenous opioids and naloxone cited 
above, CCK-antagonists have been found to block this anxiety-induced hyperalgesia 
(Benedetti, Lanotte, Lopiano, & Colloca, 2007). The implications of these effects can be 
significant and long-lasting, with some studies reporting that just one experience of a 
nocebo effect can influence the efficacy of future treatments (Colloca & Miller, 2011). In the 
context of sport and exercise science, only a handful of studies have investigated the nocebo 
effect (Beedie et al., 2007; Bottoms, Buscombe, & Nicholettos, 2014; Hurst, Foad, & Beedie, 
2017). While ethical constraints may limit how much we can learn about this phenomenon, 
the evidence from neuroscience suggests it can significantly impair sport performance and 
negatively impact exercise outcomes. It is pertinent that research in sport has shown 
performance outcomes to fall below baseline in conditions where participants believed that 
the treatment had been withheld, for example when participants are informed or suspect 
they have been assigned to the control condition (Beedie et al., 2006; Foad et al., 2008). (We 
recognise that such a scenario may not represent an “active” nocebo. In other words, being 
denied treatment may worsen performance by a different mechanism than a nocebo effect, 
where the participant believes the substance to be harmful.) 
 
Context and placebo responses. Placebo and nocebo effects encompass a wide range of 
phenomena that are not restricted to a direct response to the administration of a 
placebo/nocebo treatment. The results obtained in both the placebo and treatment arms of 
a drug trial comprise all the influences associated with administration of that drug. These 
can include but are not limited to: expectation, previous experiences, the interaction 
between participant and researcher, trust, empathy and the ritual surrounding the 
administration. In the clinical or research setting, ambiguous language such as “this stuff 
might work” is likely far less effective than definitive language such as “6mg per kg body 
weight of caffeine has been found to improve 40-km time trial performance by between 2 
and 3% among most competitive cyclists studied”. Furthermore, such instructions delivered 
by a senior professor might be more effective than when delivered by a first-year graduate 
student. A wealth of data in social psychology describes contextual factors that impact on 
treatment outcomes, some of which is reported in sport and exercise literature (Beedie, 
Foad, & Hurst, 2015; Trojian & Beedie, 2008). Collectively these and the neurophysiological 
mechanisms described above and elsewhere have been described as ‘the new physiology of 
the doctor patient relationship’ (Benedetti, 2013).  
 
Statement of problem 
 
The placebo effect is likely a factor in all sport and exercise research studies involving human 
participants, even in those with a placebo control condition. However, as we have indicated 
above, placebo and nocebo effects can be complex. For example, all other things being 
equal, in a research study or in the field, the performance of athletes or exercisers with 
positive expectations of a treatment would theoretically improve to a greater degree than 
the performance of those with either no expectation or negative expectation. Likewise, the 
performance of athletes who have habitually used a treatment – and who therefore might 
exhibit conditioned responses to that treatment – should in theory be enhanced to a greater 
degree than the performances of athletes not conditioned to that particular treatment 
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(which of course may contest ideas related to reduced effectiveness resulting from 
habituation, Bell & McLellan, 2002; Goldstein et al., 2010). Given what is known about 
placebo effects, it is not unreasonable to suggest that the placebo responsiveness of any one 
person might be a factor in their responsiveness to a wide range of biologically active 
treatments. In this context, recent research indicated that athletes who used or intended to 
use sport supplements were more placebo responsive than those that do not (Hurst et al., 
2017). However, in most experimental designs currently used, researchers would be 




At our meeting we agreed that future sport and exercise research could be enhanced by 
considering the possibility that placebo and nocebo effects might explain a significant 
percentage of outcome variance. Further, that research would benefit by incorporating 
variables that facilitate the assessment of the placebo contribution to overall treatment 
effects. We arrived at consensus on the following recommendations, all of which we believe 
are critical in enhancing knowledge in relation to the interactions between brain and body in 
sport and exercise. In proposing these recommendations, we are not proposing they are 
only relevant to increasing understanding of placebo and nocebo effects, in many respects 
each represents good practice in a wide range of research contexts beyond placebo 
research.   
 
1. Use of no-treatment groups alongside placebo and treatment groups. Such designs 
recognise the research cited above that position the placebo condition as an active 
treatment as opposed to a passive control. Elucidating such effects would not only 
improve the validity and reliability of research (under-performance among controls 
has the potential to falsely inflate the apparent effect size, whilst large placebo 
effects compared to baseline might raise questions regarding the biological 
effectiveness of the treatment), but also help us understand the effects of 
expectation and/or conditioning on treatment outcomes that might enhance 
practice. 
2. Assessment of conditioning. Researchers should use standardised measures of 
participants’ experience relating to the treatment under examination. This could help 
researchers identify the degree to which learned/acquired responses have influenced 
outcomes. This is especially important in efficacy trials when previous experiences of 
a treatment may lead to biased samples and incorrect conclusions.  
3. Assessment of expectation. Researchers should examine subjects’ perceptions of the 
treatment, for example their belief in the effect of the treatment and the degree to 
which they are certain to have benefited from it (and therefore did not ingest a 
placebo). A measure such as the Stanford Expectation of Treatments Scale (Younger, 
Gandhi, Hubbard, & Mackey, 2012) could be adapted to this context. Measures of 
expectation could assist in distinguishing placebo responders from placebo non-
responders and add to the explained variance in findings. 
4. Examination of mechanisms. Researchers should conduct more mechanistic 
research to clarify direct and placebo treatment effects. For example, the ergogenic 
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effects of caffeine on performance have been replicated using placebo caffeine, but 
questions remain as to whether there are mechanisms common to both placebo and 
real caffeine. Ingested caffeine can exert neurophysiological effects (Kaasinen, Aalto, 
Någren, & Rinne, 2004) as can caffeine that is tasted but not ingested (De Pauw et 
al., 2015). Caffeine can also elicit metabolic effects (Hodgson, Randell, & Jeukendrup, 
2013). It is possible that the effects of ingested caffeine on performance might be 
identical to those of ingested placebo caffeine, or different, for example metabolic in 
the case of real caffeine and neurobiological in the case of placebo caffeine (De Pauw 
et al., 2015; Kaasinen et al., 2004).  
5. Examination of patterns in variability. Researchers should investigate large standard 
deviations in response to treatments, specifically the possibility that these could be 
hiding relatively homogeneous sub-groups of placebo responders and placebo non-
responders. The proportion of people responding to a placebo varies from study to 
study. While there may not be a single setting in which every individual would 
respond to a placebo, findings from conditioning-based placebo research suggest 
that the capacity to respond to a placebo is perhaps more than a binary and stable 
personality trait.  
6. Consideration and measurement of contextual factors. As mentioned above, 
researchers should recognise that placebo and nocebo effects encompass a wide 
range of effects that are not just direct effects from the administration of a placebo. 
All such factors need to be considered in study design and data analysis. Certainly, 
such factors should be standardised where possible; for example, a treatment 
administered by one experimenter might differ systematically in effectiveness from 
the same treatment administered by another. In this context, fine details of 
participant contact, communication and treatment should be reported in studies. 
7. Consideration and measurement of potentially overlapping causes. Researchers 
should consider the likely overlap of effects in sport and exercise. For example, the 
apparent enhanced performance resulting from false positive feedback in a pacing 
study might theoretically be explained by motivational effects that would be evident 
in increased effort and increased physiological stress, or by placebo effects driven by 
neurobiological reward mechanisms that might not be observed in increased 
physiological stress. Likewise, administration of a placebo might enhance confidence 
that could itself result in a more effective pacing strategy and improved 
performance. Researchers should not only keep an open mind as to potentially 
overlapping mechanisms, but should seek wherever possible to measure those that 
might be implicated. Certainly, it should not be assumed that because the 
intervention was aimed at enhancing motivation or confidence, observed effects on 
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